- Home
- PULM vs PRPH Comparison
PULM vs PRPH Comparison
Compare PULM & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- PRPH
- Stock Information
- Founded
- PULM 2003
- PRPH 1989
- Country
- PULM United States
- PRPH United States
- Employees
- PULM N/A
- PRPH N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- PRPH Health Care
- Exchange
- PULM Nasdaq
- PRPH Nasdaq
- Market Cap
- PULM 18.3M
- PRPH 21.9M
- IPO Year
- PULM N/A
- PRPH 1997
- Fundamental
- Price
- PULM $4.87
- PRPH $0.38
- Analyst Decision
- PULM
- PRPH
- Analyst Count
- PULM 0
- PRPH 0
- Target Price
- PULM N/A
- PRPH N/A
- AVG Volume (30 Days)
- PULM 17.6K
- PRPH 1.6M
- Earning Date
- PULM 10-16-2025
- PRPH 11-12-2025
- Dividend Yield
- PULM N/A
- PRPH N/A
- EPS Growth
- PULM N/A
- PRPH N/A
- EPS
- PULM N/A
- PRPH N/A
- Revenue
- PULM $3,000.00
- PRPH $5,588,000.00
- Revenue This Year
- PULM N/A
- PRPH $221.82
- Revenue Next Year
- PULM $134.88
- PRPH N/A
- P/E Ratio
- PULM N/A
- PRPH N/A
- Revenue Growth
- PULM N/A
- PRPH N/A
- 52 Week Low
- PULM $2.00
- PRPH $0.22
- 52 Week High
- PULM $10.40
- PRPH $2.40
- Technical
- Relative Strength Index (RSI)
- PULM 50.82
- PRPH 40.45
- Support Level
- PULM $4.55
- PRPH $0.35
- Resistance Level
- PULM $4.95
- PRPH $0.40
- Average True Range (ATR)
- PULM 0.21
- PRPH 0.05
- MACD
- PULM 0.02
- PRPH -0.02
- Stochastic Oscillator
- PULM 46.72
- PRPH 15.22
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.